Philadelphia Chromosome Positive Recruiting Phase 2 Trials for Cefotaxime (DB00493)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT03023046Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTreatment
NCT01424982Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaTreatment